The SPOT-HPV Study

Completed

Conditions studied: HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma

In brief

The purpose of this research is to evaluate a new test for oral HPV DNA in saliva ('oral rinse test').

Key facts

Study ID

NCT05524025

Run by

Dana-Farber Cancer Institute

People needed

360

Starts

2022-11-30

Expected to finish

2026-01-01

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18+ years
• Able to provide informed consent
• Either one of the following:
• Control cohort: Male individuals WITHOUT head and neck tumors that are, or may be, HPV-positive
• Case cohort: Any individual WITH incident, untreated HPV-positive oropharynx squamous cell carcinoma

You may not qualify if…

• Unable to provide informed consent
• Head and neck tumors of non-oropharynx subsites that are or may be HPV-positive, including oral cavity, sinonasal, laryngeal, hypopharyngeal, or nasopharyngeal squamous cell carcinomas

Where it is running

• Brigham & Woman's Hospital — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.